Advertisement
UK markets closed
  • NIKKEI 225

    38,617.10
    -329.83 (-0.85%)
     
  • HANG SENG

    19,195.60
    -25.02 (-0.13%)
     
  • CRUDE OIL

    77.76
    -0.90 (-1.14%)
     
  • GOLD FUTURES

    2,391.50
    -34.40 (-1.42%)
     
  • DOW

    39,737.87
    -135.12 (-0.34%)
     
  • Bitcoin GBP

    54,851.41
    +32.08 (+0.06%)
     
  • CMC Crypto 200

    1,514.72
    -11.69 (-0.77%)
     
  • NASDAQ Composite

    16,787.75
    -44.88 (-0.27%)
     
  • UK FTSE All Share

    4,560.55
    -23.85 (-0.52%)
     

Oculis Publishes Invitation to the Annual General Meeting

Oculis Holding AG
Oculis Holding AG

Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST / 9:30 a.m. EDT.

All information pertaining to the 2024 Annual General Meeting, including meeting materials, can be accessed on the Oculis website at https://investors.oculis.com/events-presentations.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.

ADVERTISEMENT

For more information, please visit: www.oculis.com

Oculis Contacts

Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor & Media Relations

LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
1-212-915-2577